FAP-12 CAR-T

FAP-12 CAR-T is a fourth-generation chimeric antigen receptor (CAR) T-cell therapy designed to target Fibroblast Activation Protein (FAP), a type II serine protease highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of most solid malignancies. Developed by researchers at Wenzhou Medical University and Zhejiang Qixin Biotech, this construct is specifically engineered to locally secrete Interleukin-12 (IL-12) using a 2A polypeptide strategy. The secretion of IL-12 is intended to remodel the immunosuppressive tumor stroma, recruit innate immune cells, and enhance the overall anti-tumor efficacy of the T cells. Preclinical studies have demonstrated that FAP-12 CAR-T cells can effectively target both human and murine FAP and exhibit synergistic anti-tumor effects when used in combination with other tumor-antigen-targeted CAR-T cells, such as those targeting Nectin4. The therapy is currently being evaluated as part of a clinical research program for the treatment of advanced malignant solid tumors.

Other names

FAP-targeted CAR-TFAP-IL-12 CAR-TFAP-IL12 CAR-TFAP-IL 12 CAR-T